相关实验视频
Updated: Jun 22, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.0K
巴里西提尼布用于治疗严重肌痛性肌痛症:一个病例报告
Masahiro Iguchi1, Jyunichiro Honjo2, Toshiyuki Yamamoto3
1Department of Neurology, Fukushima Medical University, 1 Hikarigaoka, Fukushima City, Fukushima, Japan.
Neuromuscular disorders : NMD
|July 2, 2024
概括
这项研究详细介绍了肌痛性肌痛症 (MG) 病例,其中巴里西提尼布,Janus激酶 (JAK) 抑制剂,成功治疗了眼部症状和减少了抗体. 这为耐火性MG患者提供了新的治疗途径.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 骨髓灰质炎 (MG) 是一种影响神经肌肉结合的自身免疫性疾病,通常用免疫疗法治疗.
- 类激酶 (JAK) 抑制剂在MG中的疗效在很大程度上仍未得到研究.
- 对于一些患者来说,类固醇和pyridostigmine等标准治疗可能不足.
研究的目的:
- 报告第一个使用JAK抑制剂成功治疗抗乙胆受体抗体阳性骨髓灰质炎的病例.
- 评估JAK抑制剂巴里西提尼布对眼球肌痛性肌痛症症状和抗体标位的影响.
- 探索JAK抑制作为耐火性MG治疗策略的潜力.
主要方法:
- 一名58岁的女性患者患有眼球肌痛性肌痛症和白发性脱发症,接受了六个月的巴里西提尼布治疗.
- 该患者此前曾对类固醇和pyridostigmine有过不充分的反应.
- 通过监测MG症状,头发再生和抗乙胆受体抗体标位来评估治疗结果.
主要成果:
- 观察到眼部骨髓质疏松症症状的完全消失,包括亡.
- 发生了显著的头发再生,同时减少了MG症状.
- 在巴里西提尼布治疗期间,抗乙胆受体抗体水平下降.
- 类固醇被逐渐减少,并且在没有症状复发的情况下停止了皮里多斯蒂格.
结论:
- 巴里西丁尼,一种JAK抑制剂,在这种情况下有效地治疗了抗乙胆受体抗体阳性骨髓灰质炎.
- 克抑制可能代表了耐火性肌痛性肌痛症的新疗法.
- 这些发现表明JAK通路调节在自身免疫神经肌肉疾病中的潜在作用.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Myasthenia Gravis: Diagnostic Tests
756
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
756

